The AHA, joined by the Association of American Medical Colleges and America's Essential Hospitals, today urged a federal appeals court to expedite their appeal of a lower court’s December dismissal of the groups’ lawsuit that sought to prevent Medicare payment cuts for many hospitals in the 340B Drug Pricing Program. Today’s request asked that the United States Court of Appeals for the District of Columbia Circuit establish an expedited schedule that would ensure completion of all briefing in the appeal by no later than the beginning of April and set a date for oral argument as soon as practicable upon completion of the briefing. The request to expedite briefing is joined by the hospitals that were part of the original lawsuit challenging the payment reduction – Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. The lower court on Dec. 29 dismissed the lawsuit as premature, but it did not rule on the merits of the groups’ claim. The groups on Jan. 9 formally notified the court of their appeal.
 

Related News Articles

Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…